The company will hold conference calls after the presentation in English and Mandarin on
Late-Breaking Poster Presentation Details
Title: Long-term renal benefit with Nefecon in Chinese patients with primary immunoglobulin A nephropathy: 2-year NefIgArd trial results
Date and Time:
Session: Late-Breaking Posters [LB-PO]
Presentation No.: TH-PO1123 (Abstract 3969868)
Presentation Venue: Exhibit Halls B-D (
Conference Call Details
For English Session
Time:
Pre-Registration Link: https://www.acecamptech.com/eventDetail/60504537
Webcast Link: https://www.acecamptech.com/meeting_live/70506314/5517event_id=60504537
About
Contact:
Email: IR@everestmedicines.com
Email: jing.yang@everestmedicines.com
Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
(C) 2023 Electronic News Publishing, source